Research programme: diabetes/insulin resistance therapy - Aus Bio

Drug Profile

Research programme: diabetes/insulin resistance therapy - Aus Bio

Alternative Names: Diabetes/insulin resistance therapy research programme - Aus Bio; MD 960; MD 961; MD 962

Latest Information Update: 19 Apr 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aus Bio Limited
  • Class
  • Mechanism of Action Nitric oxide modulators; Protein-tyrosine-phosphatase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Diabetes mellitus; Insulin resistance

Most Recent Events

  • 19 Apr 2010 Preclinical development is ongoing in Australia
  • 16 Jan 2007 Preclinical development is ongoing
  • 16 Jan 2007 The MD 960 programme may be available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top